Video Programs

This episode focuses on practical decision-making for selecting among HER2-directed therapies after progression on chemo-immunotherapy.

Compare EGFR lung cancer first-line options—osimertinib, amivantamab/lazertinib, or chemo combo—balancing visits, survival, and risks.

This episode examines second-line therapy selection when brain metastases are present in HER2-mutant non-small cell lung cancer.

Zongertinib shows 77% frontline responses and 96% disease control, with rapid onset and promising durability versus other HER2 TKIs.

In this segment on advanced renal cell carcinoma, Dr. McGregor highlights the challenges of managing comorbidities in community practice and how these factors influence treatment selection. Dr. Wulff and Dr. Geynisman discuss practical strategies for adapting guideline-based therapies in patients with cardiovascular disease, pulmonary conditions, and baseline anemia.

In this segment on advanced renal cell carcinoma, Dr. Geynisman discusses how clinicians decide between single-agent TKIs and combination approaches in later-line treatment settings.

FDA‑approved zongertinib transforms HER2‑mutant NSCLC, delivering ~77% responses with less toxicity than chemo.

Limited lung cancer tissue? Pair liquid biopsy with NGS to spot actionable mutations fast and choose targeted therapy without delaying care.

Explore first-line therapy for HER2-mutated advanced NSCLC in an older patient, covering biomarker testing, liquid biopsy timing, and tailored HER2-targeted options.

Dr. Doroshow addresses the critical gap that shaped Sandra's treatment trajectory: incomplete upfront molecular testing in community oncology.

Dr. Gumbleton frames the three preferred front-line options for EGFR-driven NSCLC: osimertinib monotherapy, amivantamab plus lazertinib, and osimertinib plus chemotherapy against Mrs. Chen's stated goals of maximizing long-term survival, minimizing clinic visits, and staying chemo-free if possible.

Dr. Matthew Gumbleton introduces the case of Mrs. Chen, a 58-year-old Asian woman and never-smoker who presents with progressive shortness of breath and about 10 pounds of unintentional weight loss over 2 months.

Dr. Deborah Doroshow presents Sandra, a 54-year-old never-smoker diagnosed 14 months ago with stage IVA non-small cell lung cancer (NSCLC), adenocarcinoma subtype.

Explore why high‑risk CLL often favors continuous BTK inhibitors over time‑limited venetoclax, balancing efficacy with clinic-visit burden.

Long-term zanubrutinib keeps atrial fibrillation risk low while manageable hypertension, neutropenia and infections emerge with continued therapy.

High‑risk del17p CLL patients on single‑agent zanubrutinib show durable progression‑free survival, rivaling outcomes in standard‑risk groups.

High-risk DEL17p CLL patients show durable progression-free survival on single-agent zanubrutinib, matching outcomes seen in standard-risk groups.

Six-year data show continuous zanubrutinib keeps CLL controlled longer than bendamustine-rituximab, including high-risk del17p/TP53 patients.

New FDA-approved zongepanib boosts responses in HER2-mutant lung cancer, delivering durable control with fewer side effects than standard chemo.

Explore why rare HER2-mutant NSCLC is highly aggressive and how broad NGS testing helps identify candidates for new HER2-targeted treatments.

In this segment on advanced renal cell carcinoma, Dr. Wulff explores how the potential incorporation of belzutifan-based regimens into NCCN recommendations could influence future treatment sequencing.

In this segment on advanced renal cell carcinoma, Dr. McGregor introduces emerging data from the LITESPARK-011 study evaluating belzutifan in combination with lenvatinib compared with cabozantinib in previously treated patients.

Learn how myeloma experts sequence CAR T and bispecifics, boost MRD-negative rates, and why academic-community teamwork improves outcomes.

In this segment on advanced renal cell carcinoma, Dr. Geynisman focuses on the clinical scenarios in which cabozantinib is selected following progression on first-line therapy.

In this segment on advanced renal cell carcinoma, Dr. Wulff transitions the discussion to treatment sequencing after progression on first-line IO-based therapy.

BCMA bispecifics in relapsed myeloma deliver 60–70% responses and year-long PFS, expanding options beyond limited CAR T access.

BCMA bispecifics boost relapsed myeloma responses to 60–70% and extend PFS to 12–18 months, offering durable options beyond CAR-T.

In this segment on advanced renal cell carcinoma, Dr. McGregor focuses on how clinicians move beyond guideline recommendations when multiple appropriate treatment options are available.

In this segment on advanced renal cell carcinoma, Dr. Geynisman raises the increasingly relevant question of how prior adjuvant pembrolizumab or earlier immunotherapy exposure influences treatment selection in the metastatic setting.

In this final segment, the discussion turns to practical challenges patients face during first-line treatment with carboplatin, paclitaxel, and retifanlimab, along with key considerations for optimizing outcomes.